Genomics BioSci & Tech. Co.,Ltd. (TPE:4195)
11.70
-1.15 (-8.95%)
At close: Nov 20, 2026
Genomics BioSci & Tech. Revenue
Genomics BioSci & Tech. had revenue of 200.58M TWD in the quarter ending September 30, 2026, with 12.68% growth. This brings the company's total for the last twelve months to 740.73M, up 21.85% year-over-year. In the year 2025, Genomics BioSci & Tech. had annual revenue of 708.38M with 36.86% growth. That makes Genomics BioSci & Tech. the 33,190th largest company in the world by revenue and 1,707th in Taiwan.
Revenue (ttm)
740.73M
Revenue Growth
+21.85%
P/S Ratio
1.26
Revenue / Employee
n/a
Employees
n/a
Market Cap
936.00M
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Genomics BioSci & Tech. breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 708.38M | 190.80M | 36.86% |
| Dec 31, 2024 | 517.58M | 121.44M | 30.65% |
| Dec 31, 2023 | 396.14M | -22.86M | -5.46% |
| Dec 31, 2022 | 419.00M | 29.04M | 7.45% |
| Dec 31, 2021 | 389.97M | -53.21M | -12.01% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pet Pharm Biotech | 266.86M |
| BIONET Therapeutics | 211.96M |
| Elixiron Immunotherapeutics (Cayman) Limited | 113.34M |
| HanchorBio | 27.66M |
| Intelligene | 796.00K |
| Uwell Biopharma | 35.00K |